<DOC>
	<DOCNO>NCT00014664</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Randomized phase II trial compare effectiveness two different monoclonal antibody regimens treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare relative safety 3 different regimen monoclonal antibody Hu1D10 patient relapse refractory grade I , II , III B-cell non-Hodgkin 's lymphoma . - Compare preliminary tumor response progression-free survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive monoclonal antibody ( MOAB ) Hu1D10 IV approximately 2 hour day 1 , 8 , 15 , 22 . - Arm II : Patients receive MOAB Hu1D10 arm I high dose . - Arm III : Patients receive MOAB Hu1D10 IV day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 . Treatment arm continue absence disease progression unacceptable toxicity . Patients follow week 1 , 4 , 12 month 6 , 9 , 12 , 18 , 24 . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm relapsed refractory grade I , II , III nonHodgkin 's lymphoma ( NHL ) , include follicular , small lymphocytic , marginal zone/MALT lymphoma Previously treat radiotherapy , immunotherapy , and/or chemotherapy NHL Progression disease response since last treatment NHL 1D10+ lymphoma immunohistochemistry flow cytometry Bidimensionally measurable disease least 2 cm single dimension No CNS metastases Circulating tumor cell great 5,000/mm^3 PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 75,000/mm^3 ( unless disease relate ) Neutrophil count least 1,000/mm^3 ( unless disease relate ) Hemoglobin great 8.0 g/dL Hepatic : Bilirubin le 2.5 mg/dL SGOT le 4 time upper limit normal Renal : Creatinine le 2.5 mg/dL Cardiovascular : No clinically significant cardiac disease ( New York Heart Association class III IV ) No evidence myocardial infarction cardiac arrhythmia ( unless surgically repair ) within past 6 month Pulmonary : No clinically significant pulmonary disease Other : No malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ No significant psychiatric CNS impairment No active serious infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study Negative antiHu1D10 antibody response ( HAHA/HAMA ) HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior interferon therapy At least 3 month since prior immunotherapy No prior monoclonal antibody Hu1D10 Chemotherapy : See Disease Characteristics At least 4 week since prior cytotoxic chemotherapy Endocrine therapy : At least 4 week since prior corticosteroid ( 10 mg prednisone/day ) No concurrent corticosteroid 10 mg prednisone/day preexist disease adverse reaction Radiotherapy : See Disease Characteristics At least 4 week since prior external beam radiotherapy At least 3 month since prior radioimmunotherapy Surgery : Not specify Other : No concurrent lymphoma therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
</DOC>